This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Keflex PULSYS

Victory Pharma, Inc.

Drug Names(s): Once-Daily Cephalexin

Description: Keflex is a first generation cephalosporin. Like other members of this class, Keflex exhibits good activity against methicillin-sensitive Staphyloccus aureus and Streptococci; moderate activity against enteric Gram-(-) rods; and poor activity against Enterococci, anaerobes, methicillin-resistant Staphylococcus aureus, and Pseudomonas.

PULSYS is Advancis' oral drug delivery technology that enables once daily pulsatile dosing.

Deal Structure: In July 2004, Advancis Pharmaceutical announced that it had acquired the U.S. rights to the Keflex brand of cephalexin from Eli Lilly and Company (Lilly). Under the terms of the agreement, Advancis paid Lilly $11 million for the exclusive rights to manufacture, market and sell Keflex in the United States. In the event Advancis is able to develop and commercialize a PULSYS-based Keflex product, other cephalexin products relying on the acquired NDAs, or other pharmaceutical products using the acquired trademarks, Eli Lilly will be entitled to royalties on these new products.

In August 2010, Victory Pharma completed the acquisition of all of the assets of MiddleBrook.

Partners: Eli Lilly & Company


Keflex PULSYS News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug